08.11.2023 APONTIS PHARMA AG  DE000A3CMGM5

EQS-Adhoc: APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program


 

EQS-Ad-hoc: APONTIS PHARMA AG / Key word(s): Strategic Company Decision/Restructure of Company
APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program

08-Nov-2023 / 20:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014

APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program

Monheim am Rhein, 8 November 2023. APONTIS PHARMA AG („Company“, Ticker APPH / ISIN DE000A3CMGM5) today based on the nine-month figures of the current financial year announces a new forecast for 2023. Accordingly, the Company expects revenues of EUR 36.1 million and EBITDA before restructuring expenses of EUR -8.6 million in the 2023 financial year.

In order to return to a profitable growth path, the Company has also adopted the announced program to increase operational performance and efficiency and presented it to the works council. The objective is to achieve significant savings by reducing personnel while at the same time increasing the effectiveness of sales and marketing. The number of jobs to be reduced is currently being negotiated with the works council. For a full financial year, savings of between EUR 6.0 million and EUR 7.0 million are expected. The necessary restructuring expenses are estimated to total between EUR 5.0 million and EUR 8.0 million.

APONTIS PHARMA AG

Investor Relations
[email protected]
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
apontis-pharma.de

APONTIS PHARMA press contact

CROSS ALLIANCE communication GmbH
Sven Pauly
[email protected]
T: +49 89 125 09 0330



End of Inside Information

08-Nov-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: APONTIS PHARMA AG
Alfred-Nobel-Str. 10
40789 Monheim
Germany
E-mail: [email protected]
Internet: https://apontis-pharma.de/
ISIN: DE000A3CMGM5
WKN: A3CMGM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1768127

 
End of Announcement EQS News Service

1768127  08-Nov-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1768127&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 54,71 44,80 40,04 39,24 51,18 55,73 36,96
EBITDA1,2 12,40 2,81 -1,72 1,00 2,36 5,57 -13,28
EBITDA-Marge3 22,66 6,27 -4,30 2,55 4,61 9,99
EBIT1,4 11,74 2,50 -2,29 -0,66 0,62 3,77 -15,16
EBIT-Marge5 21,46 5,58 -5,72 -1,68 1,21 6,77 -41,02
Jahresüberschuss1 11,58 2,37 -2,39 -1,18 -0,75 2,69 -12,68
Netto-Marge6 21,17 5,29 -5,97 -3,01 -1,47 4,83 -34,31
Cashflow1,7 31,09 4,46 -0,24 1,45 3,43 11,02 -12,60
Ergebnis je Aktie8 1,36 0,28 -0,28 -0,14 -0,09 0,32 -1,49
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: RSM Ebner Stolz

INVESTOR-INFORMATIONEN
©boersengefluester.de
Apontis Pharma
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A3CMGM 9,040 Kaufen 76,84
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
24,43 25,63 0,98 47,83
KBV KCV KUV EV/EBITDA
2,54 - 2,08 -4,44
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 17.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
08.05.2024 09.08.2024 07.11.2024 28.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
23,55% 66,64% 90,32% 13,85%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu APONTIS PHARMA AG  ISIN: DE000A3CMGM5 können Sie bei EQS abrufen


Gesundheit , A3CMGM , APPH , XETR:APPH